Oppenheimer Downgrades Bio-Reference Laboratories (BRLI) to Perform
More News related to BRLI
- AirClic Mobile Business Solutions 'Clic' for Bio-Reference Laboratories, Inc.
- BioReference Laboratories, Inc. to Speak at the Jefferies 3rd Annual Healthcare Conference
- BioReference Laboratories, Inc to speak at the William Blair 29th Annual Growth Stock Conference
- Jefferies & Co Downgrades Bio-Reference Labs (BRLI) to Hold
- Morning Movers 6/4: WIND, NVAX, OCLS, AGEN, CONN, ATSI Higher; OMEX, BGP, CODI, GU, ANF Lower
Oppenheimer downgrades Bio-Reference Laboratories (Nasdaq: BRLI) from Outperform to Perform. Price target $25.
Bio-Reference Laboratories, Inc. is an independent regional clinical laboratory servicing the greater New York metropolitan area.
Related Categories
DowngradesStocks Mentioned
-1.83Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
